Full-Time

Biostatistical Manager

Confirmed live in the last 24 hours

GRAIL

GRAIL

1,001-5,000 employees

Blood tests for early cancer detection

Biotechnology
Healthcare

Compensation Overview

$159k - $199kAnnually

+ Annual Bonus + Incentive Plan + Long-term Incentive Plan

Mid, Senior

Menlo Park, CA, USA

Hybrid position requiring in-office presence.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
R
Requirements
  • PhD in Biostatistics or related field with 5+ years (or MS with 8+ years) in academia or industry experience including at least 3 years of experience in the fields of RWE and Epidemiology.
  • Molecular diagnostics or pharmaceutical industry experience preferred.
  • Familiarity with traditional performance metrics of clinical diagnostic tools.
  • Strong knowledge of theoretical and applied statistics, particularly in the fields of epidemiology, health economics and outcomes research (HEOR), and RWE (e.g., propensity score matching/weighting, longitudinal data analysis, difference-in-differences estimation, synthetic/historical control arms, indirect treatment comparisons, network meta analysis, count data regressions, parametric/non-parametric survival analysis (e.g., competing risks models, multi-state models, frailty random effects models, etc).
  • Outstanding verbal, writing, and presentation skills with a strong ability to influence and communicate effectively throughout all levels of the organization and externally.
  • Demonstrated success leading the statistical portion of post-launch product evaluation in the diagnostic/IVD or pharmaceutical industry is a plus.
  • Knowledge of applicable regulatory rules and guidelines, not limited to ICH, GCP, HIPAA, NICE, and other RWE guidelines.
  • Experience programming in R or related programming environment (e.g. SAS).
Responsibilities
  • Contribute to the preparation of study protocols, development of statistical analysis plans, implementation of innovative statistical methods, writing programs to execute analyses, and assisting with the interpretation and dissemination of findings.
  • In collaboration with cross-functional teams, lead and support reporting of clinical studies and RWE studies for regulatory submissions, health technology assessments (HTAs), and publications.
  • Assist a variety of Clinical Development and Medical Affairs activities in developing abstracts, publications, and managing ad-hoc requests.
  • Lead and support future studies that involve claims databases (e.g., MarketScan, Pharmetrics, etc), EMR/EHR (e.g., Flatiron’s oncology EHR databases), and registries.
  • Stay abreast of industry and academic developments in the Statistical Genomics and real-world evidence generation and apply to clinical study design and analysis.
  • Present some of the state-of-the-art statistical methodologies and issues via various departmental and company-wide meetings.

GRAIL focuses on improving cancer detection through advanced blood tests that identify cancer at its earliest stages, enhancing treatment success rates. The company utilizes high-intensity sequencing to analyze tumor genome data, employing algorithms and deep learning to extract actionable information for early cancer detection. GRAIL differentiates itself from competitors by conducting large-scale clinical studies to ensure the effectiveness and reliability of its tests. The primary goal is to reduce global cancer mortality by enabling early diagnosis, making the disease more treatable.

Company Stage

N/A

Total Funding

$1.8B

Headquarters

Menlo Park, California

Founded

2016

Growth & Insights
Headcount

6 month growth

-5%

1 year growth

1%

2 year growth

5%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful completion of large-scale clinical trials like PATHFINDER 2 and NHS-Galleri could solidify GRAIL's reputation and lead to widespread adoption of its Galleri test.
  • Partnerships with healthcare providers like CarePoint and WVU Medicine enhance GRAIL's market penetration and credibility in the healthcare sector.
  • The spin-off from Illumina and potential listing on Nasdaq could provide GRAIL with increased financial resources and market visibility.

What critics are saying

  • The high cost and complexity of large-scale clinical trials could strain GRAIL's financial resources and delay product rollouts.
  • Dependence on partnerships and collaborations for market penetration may limit GRAIL's control over its growth trajectory.

What makes GRAIL unique

  • GRAIL leverages high-intensity sequencing and deep learning to analyze vast amounts of tumor genome data, setting it apart from traditional cancer detection methods.
  • The company's focus on large-scale clinical studies, such as PATHFINDER 2 and NHS-Galleri, ensures robust clinical validation and performance evidence for its Galleri test.
  • GRAIL's potential to expand into direct-to-consumer sales could significantly broaden its market reach, unlike many competitors who remain focused on B2B models.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Outstanding People - Join a team of passionate and dedicated professionals, committed to collaboration, education, and proactive problem-solving.

Strong Compensation - We offer competitive salaries and savings plans to provide for long-term financial planning.

Complete Health Coverage - Take advantage of comprehensive health coverage, with medical, dental and vision, to keep you and your family healthy.

Work-Life Balance - Make everyday life more manageable with flexible time off – we trust you to do great work and take time for yourself.